Pathogen-driven gastrointestinal cancers: Time for a change in treatment paradigm?

Infectious Agents and Cancer

Volumn 7, Issue 1, 2012, Pages

  Aituov, Bauyrzhan ^a   Duisembekova, Assem ^a   Bulenova, Assel ^a   Alibek, Kenneth ^a,b  

^a NAZARBAYEV UNIVERSITY   (Kazakhstan)

^b Republican Scientific Center for Emergency Care   (Kazakhstan)

Author keywords

Colorectal cancer; Cytomegalovirus; Epstein Barr virus; Gastric cancer; Helicobacter pylori; Helminthes; Hepatitis C virus; John Cunningham virus; Liver cancer; Streptococcus bovis

Indexed keywords

CAGA PROTEIN; EPSTEIN BARR VIRUS ANTIGEN 1; VACUOLATING TOXIN;

ARTICLE; BACTERIAL COLONIZATION; CARCINOGENESIS; CLONORCHIS SINENSIS; COLORECTAL CANCER; CYTOMEGALOVIRUS; DIGESTIVE SYSTEM CANCER; DNA METHYLATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION; GENOMIC INSTABILITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFLAMMATION; LIVER CANCER; LIVER CELL CARCINOMA; MICROORGANISM; NONHUMAN; OPISTHORCHIS VIVERRINI; PATHOGENICITY ISLAND; PRIORITY JOURNAL; RISK FACTOR; SCHISTOSOMA HEMATOBIUM; STOMACH CANCER; TOXOCARIASIS; WART VIRUS;

EID: 84864542613     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-7-18     Document Type: Article

References (115)

1. Estimates of the cancer incidence and mortality in Europe in 2006. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P, Ann Oncol 2007 18 581 592 17287242 (Pubitemid 46359643)
2. Cancer statistics, 2010. Jemal A, Siegel R, Ward E, Xu J, CA Cancer J Clin 2010 60 277 300 10.3322/caac.20073 20610543
3. Gastric carcinogenesis. Bornschein J, Malfertheiner P, Langenbecks Arch Surg 2011 396 6 729 742 10.1007/s00423-011-0810-y 21611816
4. Helicobacter pylori Infection and Gastric Adenocarcinoma. Correa P, Piazuelo MB, US Gastroenterol Hepatol Rev. 2011 7 1 59 64 21857882
5. Linking epithelial polarity and carcinogenesis by multitasking Helicobacter pylori virulence factor CagA. Hatakeyama M, Oncogene 2008 27 55 7047 7054 10.1038/onc.2008.353 19029944
6. Molecular mechanisms of epithelial-barrier disruption by Helicobacter pylori. Wessler S, Backert S, Trends Microbiol 2008 16 8 397 405 10.1016/j.tim.2008.05.005 18619844
7. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Parsonnet J, Friedman GD, Orentreich N, Vogelman H, Gut 1997 40 3 297 301 9135515 (Pubitemid 27145639)
8. Infection with CagA+Helicobacter pylori strains as a possible predictor of risk in the development of gastric adenocarcinoma in Mexico. Torres J, Pérez-Pérez GI, Leal-Herrera Y, Muñoz O, Int J Cancer 1998 78 3 298 300 10.1002/(SICI)1097-0215(19981029)78:3<298::AID-IJC6>3.0.CO;2- Q 9766561 (Pubitemid 28445364)
9. Helicobacter pylori VacA-induced inhibition of GSK3 through the PI3K/Akt signaling pathway. Nakayama M, Hisatsune J, Yamasaki E, Isomoto H, Kurazono H, Hatakeyama M, Azuma T, Yamaoka Y, Yahiro K, Moss J, Hirayama T, J Biol Chem 2009 284 3 1612 1619 18996844
10. The Helicobacter pylori's protein VacA has direct effects on the regulation of cell cycle and apoptosis in gastric epithelial cells. Manente L, Perna A, Buommino E, Altucci L, Lucariello A, Citro G, Baldi A, Iaquinto G, Tufano MA, De Luca A, J Cell Physiol 2008 214 3 582 587 10.1002/jcp.21242 17786942 (Pubitemid 351224201)
11. The Helicobacter pylori blood group antigen-binding adhesin facilitates bacterial colonization and augments a nonspecific immune response. Rad R, Gerhard M, Lang R, Schöniger M, Rösch T, Schepp W, Becker I, Wagner H, Prinz C, J Immunol 2002 168 6 3033 3041 11884476 (Pubitemid 34211685)
12. Functional antagonism between Helicobacter pylori CagA and vacuolating toxin VacA in control of the NFAT signaling pathway in gastric epithelial cells. Yokoyama K, Higashi H, Ishikawa S, Fujii Y, Kondo S, Kato H, Azuma T, Wada A, Hirayama T, Aburatani H, Hatakeyama M, Proc Natl Acad Sci U S A 2005 102 27 9661 9666 10.1073/pnas.0502529102 15980153 (Pubitemid 40981737)
13. Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Saadat I, Higashi H, Obuse C, Umeda M, Murata-Kamiya N, Saito Y, Lu H, Ohnishi N, Azuma T, Suzuki A, Ohno S, Hatakeyama M, Nature 2007 447 7142 330 333 10.1038/nature05765 17507984 (Pubitemid 46788831)
14. Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Murata-Kamiya N, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H, Aburatani H, Akiyama T, Peek RM, Azuma T, Hatakeyama M, Oncogene 2007 26 32 4617 4626 10.1038/sj.onc.1210251 17237808 (Pubitemid 47067401)
15. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y, Cheng LL, Lee J, Rha SY, Chung HC, Ganesan K, So J, Soo KC, Lim D, Chan WH, Wong WK, Bowtell D, Yeoh KG, Grabsch H, Boussioutas A, Tan P, PLoS Genet 2009 5 10 1000676 10.1371/journal.pgen.1000676 19798449
16. Helicobacter pylori induces IkappaB kinase alpha nuclear translocation and chemokine production in gastric epithelial cells. Hirata Y, Maeda S, Ohmae T, Shibata W, Yanai A, Ogura K, Yoshida H, Kawabe T, Omata M, Infect Immun 2006 74 3 1452 1461 10.1128/IAI.74.3.1452-1461.2006 16495515 (Pubitemid 43346777)
17. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Oshima H, Matsunaga A, Fujimura T, Tsukamoto T, Taketo MM, Oshima M, Gastroenterology 2006 131 4 1086 1095 10.1053/j.gastro.2006.07.014 17030179 (Pubitemid 44498691)
18. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Zhang Z, Li Z, Gao C, Chen P, Chen J, Liu W, Xiao S, Lu H, Lab Invest 2008 88 12 1358 1366 10.1038/labinvest.2008.94 18794849
19. Increased miR-222 in H. pylori-associated gastric cancer correlated with tumor progression by promoting cancer cell proliferation and targeting RECK. Li N, Tang B, Zhu ED, Li BS, Zhuang Y, Yu S, Lu DS, Zou QM, Xiao B, Mao XH, FEBS Lett 2012 586 6 722 728 10.1016/j.febslet.2012.01.025 22321642
20. Global Cancer Facts and Figures, Global Cancer Facts and Figures 2 [ http://www.cancer.org/Research/CancerFactsFigures/GlobalCancerFactsFigures/ global-facts-figures-2nd-ed ]
21. p73 gene promoter methylation in Epstein-Barr virus-associated gastric carcinoma. Ushiku T, Chong JM, Uozaki H, Hino R, Chang MS, Sudo M, Rani BR, Sakuma K, Nagai H, Fukayama M, Int J Cancer 2007 120 1 60 66 10.1002/ijc.22275 17058198 (Pubitemid 44901918)
22. Epstein-Barr virus-associated gastric adenocarcinoma. Shibata D, Weiss LM, Am J Pathol 1992 140 4 769 774 1314023
23. EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. Leight ER, Sugden B, Rev Med Virol 2000 10 2 83 100 10.1002/(SICI)1099- 1654(200003/04)10:2<83::AID-RMV262>3.0.CO;2-T 10713596 (Pubitemid 30175424)
24. Epstein-Barr virus related gastric cancer in Japan: a molecular patho-epidemiological study. Tokunaga M, Uemura Y, Tokudome T, Ishidate T, Masuda H, Okazaki E, Kaneko K, Naoe S, Ito M, Okamura A, et al. Acta Pathol Jpn 1993 43 10 574 581 8291445 (Pubitemid 23303515)
25. Epstein-Barr virus-positive multiple early gastric cancers and dysplastic lesions: a case report. Arikawa J, Tokunaga M, Tashiro Y, Tanaka S, Sato E, Haraguchi K, Yamamoto A, Toyohira O, Tsuchimochi A, Pathol Int 1997 47 10 730 734 10.1111/j.1440-1827.1997.tb04450.x 9361110 (Pubitemid 27460765)
26. Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus infection of the stomach. Fukayama M, Hayashi Y, Iwasaki Y, Chong J, Ooba T, Takizawa T, Koike M, Mizutani S, Miyaki M, Hirai K, Lab Invest 1994 71 1 73 81 8041121 (Pubitemid 24246024)
27. Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA. Iwakiri D, Eizuru Y, Tokunaga M, Takada K, Cancer Res 2003 63 21 7062 7067 14612496 (Pubitemid 37413440)
28. Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Sugiura M, Imai S, Tokunaga M, Koizumi S, Uchizawa M, Okamoto K, Osato T, Br J Cancer 1996 74 4 625 631 10.1038/bjc.1996.412 8761381 (Pubitemid 26279061)
29. Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas. Luo B, Wang Y, Wang XF, Liang H, Yan LP, Huang BH, Zhao P, World J Gastroenterol 2005 11 5 629 633 15655811 (Pubitemid 40220748)
30. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, Ishikawa S, Morikawa T, Nakaya T, Sakatani T, Takada K, Fukayama M, Cancer Res 2009 69 7 2766 2774 10.1158/0008-5472.CAN-08-3070 19339266
31. Epstein-Barr virus and gastric carcinoma-viral carcinogenesis through epigenetic mechanisms. Uozaki H, Fukayama M, Int J Clin Exp Pathol 2008 1 3 198 216 18784828
32. Epstein-Barr virus (EBV) and its associated human cancers-genetics, epigenetics, pathobiology and novel therapeutics. Tao Q, Young LS, Woodman CB, Murray PG, Front Biosci 2006 11 2672 2713 10.2741/2000 16720343 (Pubitemid 43806572)
33. Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway. Stewart S, Dawson CW, Takada K, Curnow J, Moody CA, Sixbey JW, Young LS, Proc Natl Acad Sci U S A 2004 101 44 15730 15735 10.1073/pnas.0402135101 15498875 (Pubitemid 39473556)
34. Anti-apoptotic role of BARF1 in gastric cancer cells. Wang Q, Tsao SW, Ooka T, Nicholls JM, Cheung HW, Fu S, Wong YC, Wang X, Cancer Lett 2006 238 1 90 103 10.1016/j.canlet.2005.06.023 16054293 (Pubitemid 43870244)
35. Low frequency of apoptosis in Epstein-Barr virus-associated gastric carcinoma with lymphoid stroma. Ohfuji S, Osaki M, Tsujitani S, Ikeguchi M, Sairenji T, Ito H, Int J Cancer 1996 68 6 710 715 10.1002/1097-0215(19961211)68: 6<710::AID-IJC2910680602>3.0.CO;2-6 8980171 (Pubitemid 27062029)
36. Low rate of apoptosis and overexpression of bcl-2 in Epstein-Barr virus-associated gastric carcinoma. Kume T, Oshima K, Shinohara T, Takeo H, Yamashita Y, Shirakusa T, Kikuchi M, Histopathology 1999 34 6 502 509 10.1111/j.1365-2559.1999.00686.x 10383694 (Pubitemid 29284624)
37. Epstein-Barr Virus-associated Gastric Carcinoma: A Newly Defined Entity. Chen JN, He D, Tang F, Shao CK, J Clin Gastroenterol 2012 46 4 262 271 10.1097/MCG.0b013e318249c4b8 22392024
38. T-antigen of the human polyomavirus JC attenuates faithful DNA repair by forcing nuclear interaction between IRS-1 and Rad51. Trojanek J, Croul S, Ho T, Wang JY, Darbinyan A, Nowicki M, Del Valle L, Skorski T, Khalili K, Reiss K, J Cell Physiol 2006 206 1 35 46 10.1002/jcp.20425 15965906 (Pubitemid 41740715)
39. Cytogenetic findings in eleven gastric carcinomas. Seruca R, Castedo S, Correia C, Gomes P, Carneiro F, Soares P, de Jong B, Sobrinho-Simões M, Cancer Genet Cytogenet 1993 68 1 42 48 10.1016/0165-4608(93)90072-T 8330282 (Pubitemid 23225023)
40. Allelotype of gastric adenocarcinoma. Yustein AS, Harper JC, Petroni GR, Cummings OW, Moskaluk CA, Powell SM, Cancer Res 1999 59 7 1437 1441 10197609 (Pubitemid 29160106)
41. Oncogenic T-antigen of JC virus is present frequently in human gastric cancers. Shin SK, Li MS, Fuerst F, Hotchkiss E, Meyer R, Kim IT, Goel A, Boland CR, Cancer 2006 107 3 481 488 10.1002/cncr.22028 16795066 (Pubitemid 44107207)
42. Large T antigens of many polyomaviruses are able to form complexes with the retinoblastoma protein. Dyson N, Bernards R, Friend SH, Gooding LR, Hassell JA, Major EO, Pipas JM, Vandyke T, Harlow E, J Virol 1990 64 3 1353 1356 2154613 (Pubitemid 20087779)
43. Hybrid genomes of the polyomaviruses JC virus, BK virus, and simian virus 40: identification of sequences important for efficient transformation. Bollag B, Chuke WF, Frisque RJ, J Virol 1989 63 2 863 872 2536108 (Pubitemid 19057255)
44. Toxocariasis masquerading as liver and lung metastatic nodules in patents with gastrointestinal cancer: clinicopathologic study of five cases. Park S, Kim YS, Kim YJ, Kyung SY, Park JW, Jeong SH, Lee SP, Dig Dis Sci 2012 57 1 155 160 10.1007/s10620-011-1833-5 21833750
45. Microfilariae in lymph node aspirate associated with metastatic gastric carcinoma: a case report. Kumar R, Acta Cytol 2010 54 3 319 320 10.1159/000325042 20518418
46. Persistent leucocytosis as initial manifestation of Whipple's disease and development of gastric cancer in the follow up. Cadenas F, Sánchez- Lombraña JL, Pérez R, Lomo FJ, Madrigal Rubiales B, Vivas S, Rodrigo L, Rev Esp Enferm Dig 1999 91 11 785 788 10601772
47. Epidemiology and risk factors for colorectal cancer. Sandler RS, Gastroenterol Clin North Am 1996 25 717 735 10.1016/S0889-8553(05)70271-5 8960889 (Pubitemid 27022912)
48. Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist. Soreide K, Nedrebo BS, Knapp JC, Glomsaker TB, Soreide JA, Korner H, Surg Oncol 2009 18 31 50 10.1016/j.suronc.2008.06.006 18672360
49. Microbial and viral pathogens in colorectal cancer. Collins D, Hogan AM, Winter DC, Lancet Oncol 2011 12 5 504 512 10.1016/S1470-2045(10)70186-8 21067973
50. Association of Streptococcus bovis bacteremia with colonic neoplasia and extracolonic malignancy. Gold JS, Bayar S, Salem RR, Arch Surg 2004 139 760 765 10.1001/archsurg.139.7.760 15249410 (Pubitemid 38886513)
51. Profiling the humoral immune response in colon cancer patients: diagnostic antigens from Streptococcus bovis. Tjalsma H, Scholler-Guinard M, Lasonder E, Ruers TJ, Willems HL, Swinkels DW, Int J Cancer 2006 119 2127 2135 10.1002/ijc.22116 16841330 (Pubitemid 44423671)
52. Helicobacter pylori in colorectal neoplasms: is there an aetiological relationship? Jones M, Helliwell P, Pritchard C, Tharakan J, Mathew J, World J Surg Oncol 2007 5 51 10.1186/1477-7819-5-51 17498313 (Pubitemid 47108234)
53. Molecular identification of Helicobacter DNA present in human colorectal adenocarcinomas by 16S rDNA PCR amplification and pyrosequencing analysis. Grahn N, Hmani-Aifa M, Fransen K, Soderkvist P, Monstein HJ, J Med Microbiol 2005 54 1031 1035 10.1099/jmm.0.46122-0 16192433 (Pubitemid 41566772)
54. Bacteroides fragilis enterotoxin induces c-myc expression and cellular proliferation. Wu S, Morin PJ, Maouyo D, Sears CL, Gastroenterol 2003 124 392 400 10.1053/gast.2003.50047 (Pubitemid 36169256)
55. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Toprak NU, Yagci A, Gulluoglu BM, Akin ML, Demirkalem P, Celenk T, Soyletir G, Clin Microbiol Infect 2006 12 782 786 16842574 (Pubitemid 43983804)
56. Radical causes of cancer. Hussain SP, Hofseth LJ, Harris CC, Nat Rev Cancer 2003 276 276 285 (Pubitemid 37328863)
57. Cytotoxic necrotizing factor 1 from Escherichia coli and dermonecrotic toxin from Bordetella bronchiseptica induce p21(rho)-dependent tyrosine phosphorylation of focal adhesion kinase and paxillin in Swiss 3T3 cells. Lacerda HM, Pullinger GD, Lax AJ, Rozengurt E, J Biol Chem 1997 272 9587 9596 10.1074/jbc.272.14.9587 9083104 (Pubitemid 27154980)
58. Cyclomodulins: bacterial effectors that modulate the eukaryotic cell cycle. Nougayrède P, Taieb F, De Rycke J, Oswald E, Trends Microbiol 2005 13 103 110 10.1016/j.tim.2005.01.002 15737728 (Pubitemid 40311892)
59. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Cover TL, Blanke SR, Nature Rev Microbiol 2005 3 320 332 10.1038/nrmicro1095 (Pubitemid 40443725)
60. Oxyradicals and DNA damage. Marnett LJ, Carcinogenesis 2000 21 361 370 10.1093/carcin/21.3.361 10688856 (Pubitemid 30137921)
61. Attaching and effacing Escherichia coli downregulate DNA mismatch repair protein in vitro and are associated with colorectal adenocarcinomas in humans. Maddocks OD, Short AJ, Donnenberg MS, Bader S, Harrison DJ, PLoS One 2009 4 5 5517 10.1371/journal.pone.0005517 19436735
62. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Gupta RA, DuBois RN, Nat Rev Cancer 2001 1 11 21 10.1038/35094017 11900248 (Pubitemid 33741877)
63. JC virus DNA sequences are frequently present in the human upper and lower gastrointestinal tract. Ricciardiello L, Laghi L, Ramamirtham P, Chang CL, Chang DK, Randolph AE, Boland CR, Gastroenterology 2000 119 1228 1235 10.1053/gast.2000.19269 11054380
64. Association of human polyomavirus JCV with colon cancer: Evidence for interaction of viral T-antigen and beta-catenin. Enam S, Del VL, Lara C, Gan DD, Ortiz-Hidalgo C, Palazzo JP, Khalili K, Cancer Res 2002 62 7093 7101 12460931 (Pubitemid 35424105)
65. Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene. Erisman MD, Rothberg PG, Diehl RE, Morse CC, Spandorfer JM, Astrin SM, Mol Cell Biol 1985 5 1969 1976 3837853 (Pubitemid 15049156)
66. Association of JC virus T-antigen expression with the methylator phenotype in sporadic colorectal cancers. Goel A, Li MS, Nagasaka T, Shin SK, Fuerst F, Ricciardiello L, Wasserman L, Boland CR, Gastroenterology 2006 130 1950 1961 10.1053/j.gastro.2006.02.061 16762618 (Pubitemid 43816967)
67. Infection of Epstein-Barr virus in colorectal cancer in Chinese. Song LB, Zhang X, Zhang CQ, Zhang Y, Pan ZZ, Liao WT, Li MZ, Zeng MS, Ai Zheng 2006 25 1356 1360 17094901
68. Specific localization of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Harkins L, Volk AL, Samanta M, Mikolaenko I, Britt WJ, Bland KI, Cobbs CS, Lancet 2002 360 1557 1563 10.1016/S0140-6736(02)11524-8 12443594 (Pubitemid 35356371)
69. Association of human papillomavirus and colon neoplasms. Kirgan D, Manalo P, Hall M, McGregor B, Arch Surg 1990 125 862 865 10.1001/archsurg.1990. 01410190060009 2164371 (Pubitemid 20218801)
70. Analysis of colorectal cancers for human cytomegalovirus presence. Bender C, Zipeto D, Bidoia C, Costantini S, Zamò A, Menestrina F, Bertazzoni, Infect Agent Cancer 2009 4 6 10.1186/1750-9378-4-6 19371403
71. Role of E6/E7 onco-proteins of high-risk human papillomaviruses in human colorectal carcinogenesis. Ricciardi R, Ghabreau L, Yasmeen A, Darnel AD, Akil N, Al Moustafa A, Cell Cycle 2009 8 1964 1965 10.4161/cc.8.12.8618 19411835
72. Viral hepatitis B and hepatocellular carcinoma. Michielsen P, Ho E, Acta Gastroenterol Belg 2011 74 1 4 8 21563647
73. Helicobacter species and liver diseases: association or causation? Pellicano R, Ménard A, Rizzetto M, Mégraud F, Lancet Infect Dis 2008 8 4 254 260 10.1016/S1473-3099(08)70066-5 18353266 (Pubitemid 351382026)
74. Hepatocellular carcinoma. Nissen NN, Martin P, The high-risk patient. J Clin Gastroenterol 2002 35 suppl 2 79 S85
75. Hepatocellular carcinoma. Roberts LR, Gores GJ, Textbook of gastroenterology Philadelphia: Lippincott Williams & Wilkins, Yamada T, Alpers DH, Kaplowitz N, Laine L, Owyang C, Powell DW, 2003 2491 2512
76. Environmental factors and risk for hepatocellular carcinoma. Yu MC, Yuan JM, Gastroenterology 2004 127 suppl 1 72 S78 15508106
77. Hepatocellular carcinoma and hepatitis C in the United States. El-Serag HB, Hepatology 2002 36 suppl 1 74 S83 12407579
78. Hepatocellular carcinoma. An epidemiologic view. El-Serag HB, J Clin Gastroenterol 2002 35 suppl 2 72 S78 12394209
79. Antiviral therapy: why does it fail in HCV-related chronic hepatitis? Masarone M, Persico M, Expert Rev Anti Infect Ther 2011 9 5 535 543 10.1586/eri.11.10 21609265
80. The role of oncogenic viruses in the pathogenesis of hepatocellular carcinoma. Zemel R, Issachar A, Tur-Kaspa R, Clin Liver Dis 2011 15 2 261 279 10.1016/j.cld.2011.03.001 21689612
81. Viral hepatitis and liver cancer: the case of hepatitis C. Levrero M, Oncogene 2006 25 27 3834 3847 10.1038/sj.onc.1209562 16799625 (Pubitemid 43980479)
82. Oncogenic Potential of Hepatitis C Virus Proteins. Banerjee A, Ratna BR, Ranjit R, Viruses 2010 2 9 2108 2133 10.3390/v2092108 21994721
83. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Smela ME, Currier SS, Bailey EA, Essigmann JM, Carcinogenesis 2004 22 535 545 (Pubitemid 32288652)
84. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Bressac B, Kew M, Wands J, Ozturk M, Nature 1991 350 429 431 10.1038/350429a0 1672732 (Pubitemid 21912246)
85. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC, Nature 1991 350 427 428 10.1038/350427a0 1849234 (Pubitemid 21912245)
86. Aflatoxin B1 induces the transversion of G-T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Aguilar F, Hussain SP, Cerutti P, Proc Natl Acad Sci USA 1993 90 8586 8590 10.1073/pnas.90.18.8586 8397412 (Pubitemid 23277714)
87. Genetic aspects of hepatocellular carcinogenesis. Ozturk M, Semin Liver Dis 1999 19 235 242 10.1055/s-2007-1007113 10518303 (Pubitemid 29488766)
88. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, Wang N, Shao Y, Wu Z, Liu G, Wang X, Sun Z, Hepatology 2002 36 1214 1220 10.1053/jhep.2002.36366 12395332 (Pubitemid 35253438)
89. Helicobacter pylori infection in patients with liver cirrhosis: facts and fictions. Zullo A, Hassan C, Morini S, Dig Liver Dis 2003 35 3 197 205 10.1016/S1590-8658(03)00029-X 12779075 (Pubitemid 40668465)
90. Helicobacter pylori and other Helicobacter species DNA in human bile samples from patients with various hepato-biliary diseases. Tiwari SK, Khan AA, Ibrahim M, Habeeb MA, Habibullah CM, World J Gastroenterol 2006 12 2181 2186 16610018
91. Helicobacter pylori and other Helicobacter species in gallbladder and liver of patients with chronic cholecystitis detected by immunological and molecular methods. Apostolov E, Al-Soud WA, Nilsson I, Kornilovska I, Usenko V, Lyzogubov V, Gaydar Y, Wadström T, Ljungh A, Scand J Gastroenterol 2005 40 1 7 10.1080/00365520410009375 15841708
92. Hepatic temporal gene expression profiling in Helicobacter hepaticus-infected A/JCr mice. Boutin SR, Rogers AB, Shen Z, Fry RC, Love JA, Nambiar PR, Suerbaum S, Fox JG, Toxicol Pathol 2004 32 678 693 10.1080/01926230490524058 15513911 (Pubitemid 39491938)
93. The H19 endodermal enhancer is required for Igf2 activation and tumor formation in experimental liver carcinogenesis. Vernucci M, Cerrato F, Besnard N, Casola S, Pedone PV, Bruni CB, Riccio A, Oncogene 2000 19 6376 6385 10.1038/sj.onc.1204024 11175353 (Pubitemid 32641852)
94. In-vitro hepatotoxic factor in Helicobacter hepaticus, H pylori and other Helicobacter species. Taylor S, Fox JG, Yan L, J Med Microbiol 1995 42 48 52 10.1099/00222615-42-1-48 7739025
95. Expression and activity of the cytolethal distending toxin of Helicobacter hepaticus. Avenaud P, Castroviejo M, Claret S, Rosenbaum J, Mégraud F, Ménard A, Biochem Biophys Res Commun 2004 318 739 745 10.1016/j.bbrc.2004.04.089 15144901 (Pubitemid 38624217)
96. The role of helminth infections in carcinogenesis. Mayer DA, Fried B, Adv Parasitol 2007 65 239 296 18063098 (Pubitemid 350183947)
97. Monograph on the evaluation of carcinogenic risks to humans: schistosomes, liver flukes and Helicobacter pylori. WHO: International Agency for Research on Cancer 1994 61 9 175
98. Helminths in human carcinogenesis. Fried B, Reddy A, Mayer D, Cancer Lett 2011 305 2 239 249 10.1016/j.canlet.2010.07.008 20667649
99. Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected Syrian golden hamsters. Thamavit W, Bhamarapravati N, Sahaphong S, Vajrasthira S, Angsubhakorn S, Cancer Res 1978 38 4634 4639 214229 (Pubitemid 9065143)
100. Helminths and malignancy. Vennervald BJ, Polman K, Parasite Immunol 2009 31 11 686 696 10.1111/j.1365-3024.2009.01163.x 19825108
101. The global health burden of infection-associated cancers in the year. Parkin D, Int J Cancer 2006 118 3030 3044 10.1002/ijc.21731 16404738
102. Franceschi S, Infection: A Major Contributor to the Global Burden of Cancer http://www.nypcancerprevention.com/issue/11/cancer-prevention/feature/ franceschi.shtml
103. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Mégraud F, Occhialini A, Rossignol JF, Antimicrob Agents Chemother 1998 42 11 2836 2840 9797212 (Pubitemid 28501212)
104. Fifteen-Year Effects of Helicobacter pylori, Garlic, and Vitamin Treatments on Gastric Cancer Incidence and Mortality. Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, Liu WD, Hu Y, Han ZX, Crystal-Mansour S, Pee D, Blot WJ, Fraumeni JF, You WC, Gail MH, J Natl Cancer Inst 2012 104 6 488 492 10.1093/jnci/djs003 22271764
105. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ, Gut 2007 56 6 772 781 10.1136/gut.2006.101634 17170018 (Pubitemid 46854190)
106. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT, Gastroenterology 2009 137 5 1641 1648 e1-2 10.1053/j.gastro.2009.07.060 19664631
107. Lytic induction and apoptosis of Epstein-Barr virus-associated gastric cancer cell line with epigenetic modifiers and ganciclovir. Jung EJ, Lee YM, Lee BL, Chang MS, Kim WH, Cancer Lett 2007 247 1 77 83 10.1016/j.canlet.2006.03.022 16647201 (Pubitemid 44959412)
108. Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections. Hemphill A, Müller J, Esposito M, Expert Opin Pharmacother 2006 7 953 964 10.1517/14656566.7.7.953 16634717
109. Thiazolides inhibit growth and induce glutathione-S-transferase Pi (GSTP1)-dependent cell death in human colon cancer cells. Müller J, Sidler D, Nachbur U, Wastling J, Brunner T, Hemphill A, Int J Cancer 2008 123 8 1797 180 10.1002/ijc.23755 18688861
110. Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections. Hemphill A, Mueller J, Esposito M, Expert Opin Pharmacother 2006 7 7 953 964 10.1517/14656566.7.7.953 16634717
111. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Anderson VR, Curran MP, Drugs 2007 67 13 1947 1967 10.2165/00003495-200767130-00015 17722965 (Pubitemid 47347408)
112. Thiazolide-induced apoptosis in colorectal cancer cells is mediated via the Jun kinase-Bim axis and reveals glutathione-S-transferase P1 as Achilles' heel. Sidler D, Brockmann A, Mueller J, Nachbur U, Corazza N, Renzulli P, Hemphill A, Brunner T, Oncogene 2011 2011 2011 10.1038/onc.2011.575
113. NIH Consensus Statement on Management of Hepatitis C. NIH Consens State Sci Statements 2002 19 1 46 14984106
114. New direct-acting antivirals combination for the treatment of chronic hepatitis C. Asselah T, Marcellin P, Liver Int 2011 31 Suppl. 1 68 77 21205141
115. The future for the treatment of genotype 4 chronic hepatitis C. Esmat G, El Raziky M, El Kassas M, Hassany M, Gami ME, Liver Int 2012 32 Suppl 1 146 150 22212586